Hap Trading, LLC Akebia Therapeutics, Inc. Call Options Transaction History

Hap Trading, LLC

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	BUY	$0.3 - $0.46 $330 - $506	1,100 Added 5.82%	20,000 $0
Q2 2022 Aug 12, 2022	BUY	$0.32 - $0.67 $1,920 - $4,020	6,000 Added 46.51%	18,900 $0
Q1 2022 May 12, 2022	BUY	$0.72 - $2.93 $9,288 - $37,797	12,900 New	12,900 $0
Q2 2021 Aug 11, 2021	SELL	$2.83 - $4.2 $102,729 - $152,460	-36,300 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$2.92 - $5.06 $15,184 - $26,311	5,200 Added 16.72%	36,300 $4,000
Q4 2020 Feb 16, 2021	BUY	$2.22 - $3.78 $8,880 - $15,120	4,000 Added 14.76%	31,100 $2,000
Q3 2020 Nov 13, 2020	BUY	$2.39 - $13.08 $26,290 - $143,880	11,000 Added 68.32%	27,100 $5,000
Q2 2020 Aug 10, 2020	BUY	$6.67 - $13.58 $107,387 - $218,638	16,100 New	16,100 $101,000
Q1 2020 May 08, 2020	SELL	$4.1 - $10.24 $42,229 - $105,472	-10,300 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$3.16 - $6.73 $32,548 - $69,319	10,300 New	10,300 $26,000
Q1 2018 May 11, 2018	SELL	$9.53 - $15.68 $100,065 - $164,640	-10,500 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$14.24 - $19.59 $149,520 - $205,695	10,500	10,500 $8,000

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $417M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.